A University of Colorado Cancer Center study describes the laboratory synthesis of the most active component of grape seed extract, B2G2, and shows this synthesized compound induces the cell death known as apoptosis in prostate cancer cells while leaving healthy cells unharmed.
A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one of the most commonly used clinical methods.
Robert Delavalle, PhD, shows a major difference between academic journals that embrace social media and those that do not.
A University of Colorado Cancer Center review published in the journal Brain Research provides an overview of TAM family cell signaling in the central nervous system, and specifically within the cancer gioblastoma multiforme.
Moyed Miften, PhD, and CU Cancer Center colleagues show that mis-positioning of endorectal balloon during prostate cancer radiation may affect treatment success.
IASLC Names Fred R. Hirsch, MD, PhD as New CEO
November 6, 2013 · Comments Off
The International Association for the Study of Lung Cancer (IASLC) Board of Directors has selected Fred R. Hirsch, MD, PhD as the organization’s new Chief Executive Officer (CEO). Hirsch takes over for the current CEO, Paul A. Bunn, Jr., MD.
Largest Ever Study of Male Breast Cancer Treatment Shows More Mastectomy, Less Radiation Than in Female Disease
October 31, 2013 · Comments Off
University of Colorado Cancer Center researchers used data from 4,276 cases of male breast cancer and 718,587 cases of female breast cancer to show that the disease is treated differently in men than in women. Specifically, male breast cancer is treated with mastectomy more often than female breast cancer, and in cases in which locally advanced female breast cancer is commonly treated with radiation, the treatment is less used in the male disease.
Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
October 28, 2013 · Comments Off
A University of Colorado Cancer Center study published in the journal PLoS One shows that, like overflowing a dam, colorectal cancer may resist the drug bevacizumab (Avastin), by switching dependence from the main flow of VEGF-A to the "tributaries" of related growth factors including VEGF-C, VEGF-D and placental growth factor.
NTRK1: a new oncogene and target in lung cancer
October 28, 2013
The Men’s Event celebrates 40 years at Elway’s, raises $120k
December 10, 2013 · No comments
American Gastroenterological Association – Funding Opportunity
December 9, 2013 · No comments
alk drug lung cancer amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno biomarkers bladder cancer breast cancer cancer grants cancer research colorado Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma metastasis microRNA Monique Spillman Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge screening skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith